Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice

被引:151
作者
Hanniman, EA
Lambert, G
McCarthy, TC
Sinal, CJ [1 ]
机构
[1] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada
[2] Univ Nantes, Sch Med, INSERM, U539, Nantes, France
关键词
atherosclerosis; nuclear receptor; liver;
D O I
10.1194/jlr.M500390-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The farnesoid X receptor (FXR) is a bile acid-activated transcription factor that regulates the expression of genes critical for bile acid and lipid homeostasis. This study was undertaken to investigate the pathological consequences of the loss of FXR function on the risk and severity of atherosclerosis. For this purpose, FXR-deficient (FXR-/-) mice were crossed with apolipoprotein E-deficient (ApoE(-/-)) mice to generate FXR-/- ApoE(-/-) mice. Challenging these mice with a high-fat, high-cholesterol (HF/HC) diet resulted in reduced weight gain and decreased survival compared with wild-type, FXR-/-, and ApoE(-/-) mice. FXR-/- ApoE(-/-) mice also had the highest total plasma lipids and the most atherogenic lipoprotein profile. Livers from FXR-/- and FXR-/- ApoE(-/-) mice exhibited marked lipid accumulation, focal necrosis (accompanied by increased levels of plasma aspartate aminotransferase), and increased inflammatory gene expression. Measurement of en face lesion area of HF/HC-challenged mice revealed that although FXR-/- mice did not develop atherosclerosis, FXR-/- ApoE(-/-) mice had approximately double the lesion area compared with ApoE(-/-) mice. In conclusion, loss of FXR function is associated with decreased survival, increased severity of defects in lipid metabolism, and more extensive aortic plaque formation in a mouse model of atherosclerotic disease.
引用
收藏
页码:2595 / 2604
页数:10
相关论文
共 42 条
[1]  
ARNAOUT MA, 1990, BLOOD, V75, P1037
[2]   PPARs and LXRs: atherosclerosis goes nuclear [J].
Barish, GD ;
Evans, RM .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (04) :158-165
[3]   PPARs: therapeutic targets for metabolic disease [J].
Berger, JP ;
Akiyama, TE ;
Meinke, PT .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251
[4]   Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor [J].
Brobst, DE ;
Ding, XS ;
Creech, KL ;
Goodwin, B ;
Kelley, B ;
Staudinger, JL .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (02) :528-535
[5]   The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand [J].
Burris, TP ;
Montrose, C ;
Houck, KA ;
Osborne, HE ;
Bocchinfuso, WP ;
Yaden, BC ;
Cheng, CC ;
Zink, RW ;
Barr, RJ ;
Hepler, CD ;
Krishnan, V ;
Bullock, HA ;
Burris, LL ;
Galvin, RJ ;
Bramlett, K ;
Stayrook, KR .
MOLECULAR PHARMACOLOGY, 2005, 67 (03) :948-954
[6]  
CANADA S, 2002, LEADING CAUSES DEATH
[7]   SENSITIVE ENZYMATIC METHOD FOR DETERMINATION OF FREE AND ESTERIFIED TISSUE CHOLESTEROL [J].
CARLSON, SE ;
GOLDFARB, S .
CLINICA CHIMICA ACTA, 1977, 79 (03) :575-582
[8]   PPARs in atherosclerosis: the clot thickens [J].
Castrillo, A ;
Tontonoz, P .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (11) :1538-1540
[9]   Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy [J].
Chinetti-Gbaguidi, G ;
Fruchart, JC ;
Staels, B .
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (02) :177-183
[10]  
Claudel T, 2002, J CLIN INVEST, V109, P961